CircRNA markers for early diagnosis of lung adenocarcinoma and application thereof

An early diagnosis and marker technology, applied in the direction of recombinant DNA technology, DNA/RNA fragments, microbial detection/testing, etc., can solve the problems that circRNA has not been reported in lung cancer, and achieve broad clinical application prospects, strong specificity, and sensitivity sex high effect

Active Publication Date: 2017-02-22
SOUTHEAST UNIV
2 Cites 26 Cited by

AI-Extracted Technical Summary

Problems solved by technology

At present, circRNAs with early diagnostic value have been found in malignant tumors such as esophageal cance...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Abstract

The invention belongs to the technical field of biology and discloses a group of circRNA markers for early diagnosis of lung adenocarcinoma and application thereof. The circRNA marker disclosed by the invention comprises four kinds of circRNA, namely circRNA-100323, circRNA-69774, circRNA-403738 and circRNA-404449. The invention has the beneficial effects that a group of novel molecular bio-markers with diagnostic values on lung adenocarcinoma are provided. According to verifications of clinical sample cases, the group of circRNA markers have high diagnostic specificity and sensitivity on early diagnosis of lung adenocarcinoma.

Application Domain

Technology Topic

Image

  • CircRNA markers for early diagnosis of lung adenocarcinoma and application thereof
  • CircRNA markers for early diagnosis of lung adenocarcinoma and application thereof
  • CircRNA markers for early diagnosis of lung adenocarcinoma and application thereof

Examples

  • Experimental program(1)

Example Embodiment

[0020] Example 1
[0021] 1 Clinical sample collection:
[0022] Sixty pairs of paraffin tissue specimens of early (stage IA) lung adenocarcinoma and their paired normal lung tissues were collected from Zhongda Hospital Affiliated to Southeast University during 2013-2014. All patients signed an informed consent to participate in the scientific research.
[0023] 2 circRNA quantitative PCR experiment:
[0024] 2.1 RNA extraction and quantitative PCR
[0025] Total RNA was extracted from tissues using Trizol, and RNA was quantified using a microvolume spectrophotometer.
[0026] 2.2 Primers
[0027] A set of circRNAs provided by the present invention includes 8 circRNAs including circRNA_100323, circRNA_69774, circRNA_403738, circRNA_404449, circRNA_104855, circRNA_100983, circRNA_1011969, and circRNA_006718. They were all selected from the results of circRNA chip detection in patients with early lung adenocarcinoma, with GAPDH as the internal reference gene (SEQ ID No: 27), and the primer sequences are shown in Table 1:
[0028] Table 1 Primer sequences used in quantitative PCR
[0029]
[0030]
[0031] 2.3 Reverse transcription reaction
[0032] The TakaRa PrimeScript RT reagent Kit kit was used for reverse transcription. The initial amount of RNA was 1 μg. The amount of reverse transcription reaction components was shown in Table 2. The reaction conditions were: 37°C for 15 minutes, 85°C for 5 sec, and then stored at low temperature for later use.
[0033] Table 2 Reverse transcription reaction system composition
[0034]
[0035] 2.4 Real-time quantitative PCR reaction
[0036] The real-time quantitative PCR used the SYBR Premix Ex Taq (Tli RnaseH Plus) kit from TaKaRa Company, and the quantitative instrument was CFX96 real-time PCR instrument from BioRad Company. The reaction system is shown in Table 3, the reaction conditions are as shown in Table 5, and each real-time quantitative PCR reaction was repeated three times.
[0037] Table 3 Real-time quantitative PCR reaction system
[0038]
[0039] The reaction program is: 95°C for 2min; 95°C for 30sec, 56°C for 50sec, 40 cycles.
[0040] The data are expressed in the form of mean ± standard deviation, and SPSS 18.0 software was used for statistical analysis of the data. Unless otherwise specified. The paired sample t-test method was used to analyze the differences in the expression of circRNAs between lung adenocarcinoma and its paired normal lung tissues. All P values ​​were two-sided, and P<0.05 was considered statistically significant.
[0041] 2.5 Evaluation of the ability of 8 circRNAs to distinguish lung adenocarcinoma and its paired normal lung tissue
[0042]We utilized ROC curves to evaluate the ability of these 8 to distinguish lung adenocarcinoma from its paired normal lung tissue. The AUC of a single circRNA for the diagnosis of lung adenocarcinoma was 0.53-0.75, the sensitivity was 54.4%-77.4%, and the specificity was 49.1%-77.5% (Table 4). We combined these 8 circRNAs for the diagnosis of 30 pairs of lung adenocarcinoma samples, and the AUC value can reach 0.854 ( figure 1 ), after choosing a suitable threshold, the sensitivity and specificity were 80.1% and 83.3%, respectively.
[0043] Table 4 The expression of 8 circRNAs in the training set (30 pairs of samples)
[0044]
[0045] 2.6 Evaluation of the ability of the four preferred circRNAs to distinguish lung adenocarcinoma and its paired normal lung tissue
[0046] Through linear logistic regression analysis, we analyzed and optimized 4 circRNAs from 8 circRNAs. We used ROC curves to evaluate the ability of 4 to distinguish lung adenocarcinoma from its paired normal lung tissue in the training set (the same 30 pairs of samples used as in 2.5). The AUC of these four circRNAs combined to distinguish early lung adenocarcinoma from paired normal lung tissue can reach 0.820 ( figure 2 shown), close to the combined detection level of 8 circRNAs, and significantly higher than the AUC of these 4 circRNAs alone in the diagnosis of early lung adenocarcinoma (P<0.05). After selecting an appropriate threshold, the ROC curve showed that the sensitivity and specificity of the four circRNAs in the diagnosis of early lung adenocarcinoma were 83.3% and 80.0%, which were significantly higher than the sensitivity and specificity of a single circRNA for the diagnosis of lung adenocarcinoma (P <0.05).
[0047] Table 5 Diagnostic results of 4 circRNAs in the validation set (30 pairs of samples)
[0048]
[0049] We verified the detection characteristics of these four circRNAs screened from the training set in another set of 30 lung adenocarcinoma samples and their paired normal lung tissues (validation set). These four circRNAs were significantly differentially expressed in lung adenocarcinoma and its paired normal lung tissues (P<0.001). The AUC of a single circRNA for the detection of lung adenocarcinoma was 0.73-0.82, the sensitivity was 65.6%-79.3%, and the specificity was 67.9%-76.3% (Table 5). The AUC of 60 pairs of lung adenocarcinoma samples jointly detected by these 4 circRNAs can reach 0.841 ( image 3 ), after selecting an appropriate threshold, the ROC curve showed that its sensitivity was 83.4%, and its specificity was 73.5%, which were significantly higher than the detection ability of any single circRNA (P<0.05). Moreover, this group of circRNAs has similar detection capabilities in two independent samples (training set and validation set), indicating that this group of circRNAs can be used as biomarkers for early detection of lung adenocarcinoma.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

no PUM

Description & Claims & Application Information

We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Similar technology patents

Vesicles for use in biosensors

InactiveUS20090325171A1Strong specificityLow nonspecific bindingSugar derivativesMicrobiological testing/measurementReceptor for activated C kinase 1Biosensor
Owner:BIOCURE

Classification and recommendation of technical efficacy words

  • High sensitivity
  • Strong specificity

System and method for optical coherence imaging

ActiveUS20060055936A1Sufficient signal to noise ratioHigh sensitivityInterferometersScattering properties measurementsPhysicsCoherent imaging
Owner:THE GENERAL HOSPITAL CORP

Catheter-free implantable needle biosensor

ActiveUS20080033269A1High sensitivitySimple stepSurgeryVaccination/ovulation diagnosticsNeedle electrodeElectricity
Owner:VIRTUE MEDICAL TECH (HUZHOU) CO LTD

Cas9-foki fusion proteins and uses thereof

ActiveUS20150071899A1Strong specificityReduce the possibilityFusion with DNA-binding domainPeptide/protein ingredientsResearch settingNuclease
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

c-MET MODULATORS AND METHOD OF USE

InactiveUS20070179130A1Strong specificityEliminate side effectsBiocideSenses disorderSignal transductionCellular activity
Owner:EXELIXIS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products